jtx2011

Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. It exhibits anti-tumor immune effects and can improve metastatic non-small cell lung cancer.

Vopratelimab (MouseIgG2a) is a monoclonal antibody that selectively targets the inducible T-cell co-stimulator (ICOS). The variable region of Vopratelimab (MouseIgG2a) matches that of Vopratelimab, while its constant region is based on the mouse IgG2a sequence. Vopratelimab (MouseIgG2a) promotes anti-tumor immune responses and enhances the efficacy of combination therapy with anti-PD-1.